nodes	percent_of_prediction	percent_of_DWPC	metapath
Eprosartan—AGTR1—pancreatic cancer	0.556	1	CbGaD
Eprosartan—ABCC2—Tamoxifen—pancreatic cancer	0.076	0.257	CbGbCtD
Eprosartan—ABCC2—Irinotecan—pancreatic cancer	0.0583	0.197	CbGbCtD
Eprosartan—ABCC2—Docetaxel—pancreatic cancer	0.0427	0.145	CbGbCtD
Eprosartan—ABCC2—Sunitinib—pancreatic cancer	0.0426	0.144	CbGbCtD
Eprosartan—ABCC2—Doxorubicin—pancreatic cancer	0.0319	0.108	CbGbCtD
Eprosartan—CYP2C9—Tamoxifen—pancreatic cancer	0.0255	0.0863	CbGbCtD
Eprosartan—CYP2C9—Fluorouracil—pancreatic cancer	0.0188	0.0636	CbGbCtD
Eprosartan—ABCC2—bile duct—pancreatic cancer	0.00849	0.524	CbGeAlD
Eprosartan—ABCC2—bile—pancreatic cancer	0.00653	0.403	CbGeAlD
Eprosartan—Losartan—AGTR1—pancreatic cancer	0.00171	1	CrCbGaD
Eprosartan—ABCC2—digestive system—pancreatic cancer	0.000713	0.044	CbGeAlD
Eprosartan—AGTR1—Peptide GPCRs—SSTR3—pancreatic cancer	0.000697	0.0293	CbGpPWpGaD
Eprosartan—AGTR1—Peptide GPCRs—SSTR1—pancreatic cancer	0.000669	0.0281	CbGpPWpGaD
Eprosartan—AGTR1—Peptide GPCRs—SSTR2—pancreatic cancer	0.000644	0.027	CbGpPWpGaD
Eprosartan—AGTR1—Peptide GPCRs—CCKBR—pancreatic cancer	0.000622	0.0261	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—FGF13—pancreatic cancer	0.000609	0.0256	CbGpPWpGaD
Eprosartan—CYP2C9—digestive system—pancreatic cancer	0.000475	0.0293	CbGeAlD
Eprosartan—AGTR1—Peptide GPCRs—CCKAR—pancreatic cancer	0.000463	0.0195	CbGpPWpGaD
Eprosartan—AGTR1—Peptide ligand-binding receptors—PRLHR—pancreatic cancer	0.000386	0.0162	CbGpPWpGaD
Eprosartan—AGTR1—Arf6 signaling events—MET—pancreatic cancer	0.000375	0.0157	CbGpPWpGaD
Eprosartan—AGTR1—Arf6 signaling events—EGF—pancreatic cancer	0.000349	0.0147	CbGpPWpGaD
Eprosartan—AGTR1—ACE Inhibitor Pathway—TGFB1—pancreatic cancer	0.000345	0.0145	CbGpPWpGaD
Eprosartan—AGTR1—Peptide ligand-binding receptors—SSTR3—pancreatic cancer	0.000328	0.0138	CbGpPWpGaD
Eprosartan—AGTR1—Peptide ligand-binding receptors—SSTR1—pancreatic cancer	0.000314	0.0132	CbGpPWpGaD
Eprosartan—AGTR1—Peptide ligand-binding receptors—PPY—pancreatic cancer	0.000308	0.013	CbGpPWpGaD
Eprosartan—AGTR1—Peptide ligand-binding receptors—SSTR2—pancreatic cancer	0.000303	0.0127	CbGpPWpGaD
Eprosartan—AGTR1—GPCRs, Class A Rhodopsin-like—PRLHR—pancreatic cancer	0.000302	0.0127	CbGpPWpGaD
Eprosartan—AGTR1—G alpha (q) signalling events—CCKBR—pancreatic cancer	0.000296	0.0124	CbGpPWpGaD
Eprosartan—AGTR1—Peptide ligand-binding receptors—CCKBR—pancreatic cancer	0.000292	0.0123	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—CCKBR—pancreatic cancer	0.000265	0.0111	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—PRLHR—pancreatic cancer	0.000259	0.0109	CbGpPWpGaD
Eprosartan—AGTR1—GPCRs, Class A Rhodopsin-like—SSTR3—pancreatic cancer	0.000257	0.0108	CbGpPWpGaD
Eprosartan—AGTR1—Arf6 trafficking events—CDH1—pancreatic cancer	0.000256	0.0108	CbGpPWpGaD
Eprosartan—AGTR1—G alpha (q) signalling events—GAST—pancreatic cancer	0.000255	0.0107	CbGpPWpGaD
Eprosartan—AGTR1—GPCRs, Class A Rhodopsin-like—SSTR1—pancreatic cancer	0.000246	0.0103	CbGpPWpGaD
Eprosartan—AGTR1—GPCRs, Class A Rhodopsin-like—SSTR2—pancreatic cancer	0.000237	0.00996	CbGpPWpGaD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MMP2—pancreatic cancer	0.000235	0.00988	CbGpPWpGaD
Eprosartan—AGTR1—G alpha (q) signalling events—CCK—pancreatic cancer	0.00023	0.00968	CbGpPWpGaD
Eprosartan—AGTR1—GPCRs, Class A Rhodopsin-like—CCKBR—pancreatic cancer	0.000229	0.00962	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GAST—pancreatic cancer	0.000228	0.00957	CbGpPWpGaD
Eprosartan—AGTR1—Peptide ligand-binding receptors—CCK—pancreatic cancer	0.000227	0.00955	CbGpPWpGaD
Eprosartan—AGTR1—G alpha (q) signalling events—CCKAR—pancreatic cancer	0.000221	0.00928	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—SSTR3—pancreatic cancer	0.00022	0.00924	CbGpPWpGaD
Eprosartan—AGTR1—Peptide ligand-binding receptors—CCKAR—pancreatic cancer	0.000218	0.00916	CbGpPWpGaD
Eprosartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—pancreatic cancer	0.000218	0.00914	CbGpPWpGaD
Eprosartan—AGTR1—Arf6 signaling events—SRC—pancreatic cancer	0.000217	0.0091	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—SSTR1—pancreatic cancer	0.000211	0.00886	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—PPY—pancreatic cancer	0.000207	0.00869	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—CCK—pancreatic cancer	0.000206	0.00865	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—SSTR2—pancreatic cancer	0.000203	0.00853	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—CCKAR—pancreatic cancer	0.000197	0.0083	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—PRLHR—pancreatic cancer	0.000197	0.00828	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCKBR—pancreatic cancer	0.000196	0.00824	CbGpPWpGaD
Eprosartan—AGTR1—Arf6 signaling events—EGFR—pancreatic cancer	0.00019	0.00798	CbGpPWpGaD
Eprosartan—AGTR1—Arf6 trafficking events—CTNNB1—pancreatic cancer	0.000189	0.00796	CbGpPWpGaD
Eprosartan—AGTR1—GPCRs, Class A Rhodopsin-like—CNR2—pancreatic cancer	0.000173	0.00729	CbGpPWpGaD
Eprosartan—AGTR1—Peptide ligand-binding receptors—SST—pancreatic cancer	0.000172	0.00724	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—NFE2L2—pancreatic cancer	0.000171	0.00717	CbGpPWpGaD
Eprosartan—AGTR1—GPCRs, Class A Rhodopsin-like—CCKAR—pancreatic cancer	0.000171	0.00717	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—SSTR3—pancreatic cancer	0.000168	0.00704	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—FXYD3—pancreatic cancer	0.000166	0.00697	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—TGFA—pancreatic cancer	0.000163	0.00684	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—SSTR1—pancreatic cancer	0.000161	0.00675	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—SLC2A2—pancreatic cancer	0.000159	0.0067	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—PPY—pancreatic cancer	0.000158	0.00662	CbGpPWpGaD
Eprosartan—AGTR1—G alpha (q) signalling events—GCG—pancreatic cancer	0.000156	0.00654	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—SSTR2—pancreatic cancer	0.000155	0.0065	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCK—pancreatic cancer	0.000152	0.00641	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—CCKBR—pancreatic cancer	0.000149	0.00627	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CNR2—pancreatic cancer	0.000149	0.00624	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCKAR—pancreatic cancer	0.000146	0.00614	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GCG—pancreatic cancer	0.000139	0.00585	CbGpPWpGaD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—pancreatic cancer	0.000136	0.00571	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—CXCL8—pancreatic cancer	0.000135	0.00569	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—SLC29A1—pancreatic cancer	0.000135	0.00568	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—CASP3—pancreatic cancer	0.00013	0.00545	CbGpPWpGaD
Eprosartan—Migraine—Doxorubicin—pancreatic cancer	0.000126	0.00118	CcSEcCtD
Eprosartan—Hypokalaemia—Epirubicin—pancreatic cancer	0.000126	0.00118	CcSEcCtD
Eprosartan—Fatigue—Irinotecan—pancreatic cancer	0.000126	0.00118	CcSEcCtD
Eprosartan—Paraesthesia—Fluorouracil—pancreatic cancer	0.000126	0.00117	CcSEcCtD
Eprosartan—Pruritus—Sunitinib—pancreatic cancer	0.000126	0.00117	CcSEcCtD
Eprosartan—Pain—Irinotecan—pancreatic cancer	0.000125	0.00117	CcSEcCtD
Eprosartan—Constipation—Irinotecan—pancreatic cancer	0.000125	0.00117	CcSEcCtD
Eprosartan—Aspartate aminotransferase increased—Epirubicin—pancreatic cancer	0.000125	0.00117	CcSEcCtD
Eprosartan—Dyspnoea—Fluorouracil—pancreatic cancer	0.000125	0.00117	CcSEcCtD
Eprosartan—Somnolence—Fluorouracil—pancreatic cancer	0.000125	0.00116	CcSEcCtD
Eprosartan—AGTR1—GPCRs, Class A Rhodopsin-like—CNR1—pancreatic cancer	0.000124	0.00523	CbGpPWpGaD
Eprosartan—Face oedema—Doxorubicin—pancreatic cancer	0.000124	0.00116	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—PIK3CA—pancreatic cancer	0.000124	0.00521	CbGpPWpGaD
Eprosartan—Decreased appetite—Gemcitabine—pancreatic cancer	0.000124	0.00116	CcSEcCtD
Eprosartan—Dyspepsia—Fluorouracil—pancreatic cancer	0.000123	0.00115	CcSEcCtD
Eprosartan—Nausea—Tamoxifen—pancreatic cancer	0.000123	0.00115	CcSEcCtD
Eprosartan—Fatigue—Gemcitabine—pancreatic cancer	0.000123	0.00115	CcSEcCtD
Eprosartan—Gastritis—Epirubicin—pancreatic cancer	0.000123	0.00115	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—HSPA1A—pancreatic cancer	0.000123	0.00515	CbGpPWpGaD
Eprosartan—Muscular weakness—Epirubicin—pancreatic cancer	0.000122	0.00114	CcSEcCtD
Eprosartan—Alanine aminotransferase increased—Epirubicin—pancreatic cancer	0.000122	0.00114	CcSEcCtD
Eprosartan—Constipation—Gemcitabine—pancreatic cancer	0.000122	0.00114	CcSEcCtD
Eprosartan—Pain—Gemcitabine—pancreatic cancer	0.000122	0.00114	CcSEcCtD
Eprosartan—Nausea—Erlotinib—pancreatic cancer	0.000122	0.00114	CcSEcCtD
Eprosartan—Decreased appetite—Fluorouracil—pancreatic cancer	0.000122	0.00114	CcSEcCtD
Eprosartan—AGTR1—GPCR ligand binding—SCT—pancreatic cancer	0.000122	0.00511	CbGpPWpGaD
Eprosartan—Diarrhoea—Sunitinib—pancreatic cancer	0.000121	0.00113	CcSEcCtD
Eprosartan—Ataxia—Doxorubicin—pancreatic cancer	0.000121	0.00113	CcSEcCtD
Eprosartan—Feeling abnormal—Irinotecan—pancreatic cancer	0.000121	0.00113	CcSEcCtD
Eprosartan—Blood creatinine increased—Doxorubicin—pancreatic cancer	0.00012	0.00112	CcSEcCtD
Eprosartan—Asthma—Epirubicin—pancreatic cancer	0.00012	0.00112	CcSEcCtD
Eprosartan—Back pain—Docetaxel—pancreatic cancer	0.00012	0.00112	CcSEcCtD
Eprosartan—Pain—Fluorouracil—pancreatic cancer	0.00012	0.00112	CcSEcCtD
Eprosartan—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.00012	0.00112	CcSEcCtD
Eprosartan—Muscle spasms—Docetaxel—pancreatic cancer	0.000119	0.00111	CcSEcCtD
Eprosartan—Dizziness—Sunitinib—pancreatic cancer	0.000117	0.0011	CcSEcCtD
Eprosartan—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000117	0.0011	CcSEcCtD
Eprosartan—Orthostatic hypotension—Doxorubicin—pancreatic cancer	0.000117	0.00109	CcSEcCtD
Eprosartan—Hypokalaemia—Doxorubicin—pancreatic cancer	0.000117	0.00109	CcSEcCtD
Eprosartan—Angina pectoris—Epirubicin—pancreatic cancer	0.000117	0.00109	CcSEcCtD
Eprosartan—AGTR1—GPCR ligand binding—CCK—pancreatic cancer	0.000116	0.00488	CbGpPWpGaD
Eprosartan—Abdominal pain—Irinotecan—pancreatic cancer	0.000116	0.00108	CcSEcCtD
Eprosartan—Body temperature increased—Irinotecan—pancreatic cancer	0.000116	0.00108	CcSEcCtD
Eprosartan—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	0.000116	0.00108	CcSEcCtD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—SST—pancreatic cancer	0.000116	0.00486	CbGpPWpGaD
Eprosartan—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000115	0.00108	CcSEcCtD
Eprosartan—Bronchitis—Epirubicin—pancreatic cancer	0.000115	0.00108	CcSEcCtD
Eprosartan—Gastritis—Doxorubicin—pancreatic cancer	0.000114	0.00106	CcSEcCtD
Eprosartan—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	0.000113	0.00106	CcSEcCtD
Eprosartan—Muscular weakness—Doxorubicin—pancreatic cancer	0.000113	0.00106	CcSEcCtD
Eprosartan—AGTR1—GPCR ligand binding—CNR2—pancreatic cancer	0.000113	0.00476	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—GLP1R—pancreatic cancer	0.000113	0.00476	CbGpPWpGaD
Eprosartan—Vomiting—Sunitinib—pancreatic cancer	0.000113	0.00105	CcSEcCtD
Eprosartan—Body temperature increased—Gemcitabine—pancreatic cancer	0.000113	0.00105	CcSEcCtD
Eprosartan—Rash—Sunitinib—pancreatic cancer	0.000112	0.00105	CcSEcCtD
Eprosartan—Dermatitis—Sunitinib—pancreatic cancer	0.000112	0.00104	CcSEcCtD
Eprosartan—Upper respiratory tract infection—Epirubicin—pancreatic cancer	0.000111	0.00104	CcSEcCtD
Eprosartan—AGTR1—GPCR ligand binding—CCKAR—pancreatic cancer	0.000111	0.00468	CbGpPWpGaD
Eprosartan—Urticaria—Fluorouracil—pancreatic cancer	0.000111	0.00104	CcSEcCtD
Eprosartan—Headache—Sunitinib—pancreatic cancer	0.000111	0.00104	CcSEcCtD
Eprosartan—Syncope—Docetaxel—pancreatic cancer	0.000111	0.00104	CcSEcCtD
Eprosartan—Asthma—Doxorubicin—pancreatic cancer	0.000111	0.00104	CcSEcCtD
Eprosartan—Pollakiuria—Epirubicin—pancreatic cancer	0.000111	0.00103	CcSEcCtD
Eprosartan—Body temperature increased—Fluorouracil—pancreatic cancer	0.000111	0.00103	CcSEcCtD
Eprosartan—AGTR1—Allograft Rejection—VEGFA—pancreatic cancer	0.00011	0.00462	CbGpPWpGaD
Eprosartan—Palpitations—Docetaxel—pancreatic cancer	0.000109	0.00102	CcSEcCtD
Eprosartan—Loss of consciousness—Docetaxel—pancreatic cancer	0.000109	0.00102	CcSEcCtD
Eprosartan—Hyperglycaemia—Epirubicin—pancreatic cancer	0.000108	0.00101	CcSEcCtD
Eprosartan—Cough—Docetaxel—pancreatic cancer	0.000108	0.00101	CcSEcCtD
Eprosartan—Angina pectoris—Doxorubicin—pancreatic cancer	0.000108	0.00101	CcSEcCtD
Eprosartan—Hypersensitivity—Irinotecan—pancreatic cancer	0.000108	0.00101	CcSEcCtD
Eprosartan—Bronchitis—Doxorubicin—pancreatic cancer	0.000107	0.000996	CcSEcCtD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CNR1—pancreatic cancer	0.000107	0.00448	CbGpPWpGaD
Eprosartan—Arthralgia—Docetaxel—pancreatic cancer	0.000105	0.000985	CcSEcCtD
Eprosartan—Myalgia—Docetaxel—pancreatic cancer	0.000105	0.000985	CcSEcCtD
Eprosartan—Chest pain—Docetaxel—pancreatic cancer	0.000105	0.000985	CcSEcCtD
Eprosartan—Nausea—Sunitinib—pancreatic cancer	0.000105	0.000985	CcSEcCtD
Eprosartan—Renal failure—Epirubicin—pancreatic cancer	0.000105	0.000981	CcSEcCtD
Eprosartan—Asthenia—Irinotecan—pancreatic cancer	0.000105	0.00098	CcSEcCtD
Eprosartan—Neuropathy peripheral—Epirubicin—pancreatic cancer	0.000105	0.000979	CcSEcCtD
Eprosartan—Conjunctivitis—Epirubicin—pancreatic cancer	0.000104	0.00097	CcSEcCtD
Eprosartan—Urinary tract infection—Epirubicin—pancreatic cancer	0.000104	0.00097	CcSEcCtD
Eprosartan—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000103	0.000964	CcSEcCtD
Eprosartan—Dry mouth—Docetaxel—pancreatic cancer	0.000103	0.000963	CcSEcCtD
Eprosartan—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.000103	0.000963	CcSEcCtD
Eprosartan—Pollakiuria—Doxorubicin—pancreatic cancer	0.000102	0.000957	CcSEcCtD
Eprosartan—Asthenia—Gemcitabine—pancreatic cancer	0.000102	0.000954	CcSEcCtD
Eprosartan—Haematuria—Epirubicin—pancreatic cancer	0.000102	0.000952	CcSEcCtD
Eprosartan—AGTR1—GPCR ligand binding—SHH—pancreatic cancer	0.000102	0.00427	CbGpPWpGaD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—AKT1—pancreatic cancer	0.000101	0.00425	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PRLHR—pancreatic cancer	0.000101	0.00425	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—TGFB1—pancreatic cancer	0.000101	0.00424	CbGpPWpGaD
Eprosartan—Epistaxis—Epirubicin—pancreatic cancer	0.000101	0.000942	CcSEcCtD
Eprosartan—Pruritus—Gemcitabine—pancreatic cancer	0.000101	0.000941	CcSEcCtD
Eprosartan—Sinusitis—Epirubicin—pancreatic cancer	0.0001	0.000937	CcSEcCtD
Eprosartan—AGTR1—GPCR ligand binding—IAPP—pancreatic cancer	0.0001	0.00421	CbGpPWpGaD
Eprosartan—Hyperglycaemia—Doxorubicin—pancreatic cancer	0.0001	0.000935	CcSEcCtD
Eprosartan—Diarrhoea—Irinotecan—pancreatic cancer	0.0001	0.000934	CcSEcCtD
Eprosartan—Shock—Docetaxel—pancreatic cancer	9.95e-05	0.000929	CcSEcCtD
Eprosartan—Pruritus—Fluorouracil—pancreatic cancer	9.91e-05	0.000925	CcSEcCtD
Eprosartan—Thrombocytopenia—Docetaxel—pancreatic cancer	9.9e-05	0.000924	CcSEcCtD
Eprosartan—Tachycardia—Docetaxel—pancreatic cancer	9.87e-05	0.000921	CcSEcCtD
Eprosartan—Bradycardia—Epirubicin—pancreatic cancer	9.77e-05	0.000912	CcSEcCtD
Eprosartan—Diarrhoea—Gemcitabine—pancreatic cancer	9.75e-05	0.00091	CcSEcCtD
Eprosartan—Renal failure—Doxorubicin—pancreatic cancer	9.72e-05	0.000908	CcSEcCtD
Eprosartan—Neuropathy peripheral—Doxorubicin—pancreatic cancer	9.7e-05	0.000906	CcSEcCtD
Eprosartan—Dizziness—Irinotecan—pancreatic cancer	9.67e-05	0.000903	CcSEcCtD
Eprosartan—Anorexia—Docetaxel—pancreatic cancer	9.64e-05	0.0009	CcSEcCtD
Eprosartan—AGTR1—GPCR ligand binding—PTCH1—pancreatic cancer	9.62e-05	0.00404	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—PTHLH—pancreatic cancer	9.62e-05	0.00404	CbGpPWpGaD
Eprosartan—Rhinitis—Epirubicin—pancreatic cancer	9.62e-05	0.000899	CcSEcCtD
Eprosartan—Urinary tract infection—Doxorubicin—pancreatic cancer	9.62e-05	0.000898	CcSEcCtD
Eprosartan—Conjunctivitis—Doxorubicin—pancreatic cancer	9.62e-05	0.000898	CcSEcCtD
Eprosartan—Diarrhoea—Fluorouracil—pancreatic cancer	9.58e-05	0.000895	CcSEcCtD
Eprosartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—pancreatic cancer	9.56e-05	0.00402	CbGpPWpGaD
Eprosartan—Pharyngitis—Epirubicin—pancreatic cancer	9.53e-05	0.00089	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—SSTR3—pancreatic cancer	9.47e-05	0.00398	CbGpPWpGaD
Eprosartan—Oedema peripheral—Epirubicin—pancreatic cancer	9.46e-05	0.000883	CcSEcCtD
Eprosartan—Hypotension—Docetaxel—pancreatic cancer	9.45e-05	0.000882	CcSEcCtD
Eprosartan—Haematuria—Doxorubicin—pancreatic cancer	9.43e-05	0.000881	CcSEcCtD
Eprosartan—AGTR1—Allograft Rejection—TNF—pancreatic cancer	9.43e-05	0.00396	CbGpPWpGaD
Eprosartan—Epistaxis—Doxorubicin—pancreatic cancer	9.33e-05	0.000871	CcSEcCtD
Eprosartan—Vomiting—Irinotecan—pancreatic cancer	9.3e-05	0.000868	CcSEcCtD
Eprosartan—Sinusitis—Doxorubicin—pancreatic cancer	9.28e-05	0.000867	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—GDI1—pancreatic cancer	9.27e-05	0.00389	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—GDI2—pancreatic cancer	9.27e-05	0.00389	CbGpPWpGaD
Eprosartan—Dizziness—Fluorouracil—pancreatic cancer	9.26e-05	0.000865	CcSEcCtD
Eprosartan—Visual impairment—Epirubicin—pancreatic cancer	9.25e-05	0.000864	CcSEcCtD
Eprosartan—Rash—Irinotecan—pancreatic cancer	9.22e-05	0.000861	CcSEcCtD
Eprosartan—Dermatitis—Irinotecan—pancreatic cancer	9.21e-05	0.00086	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	9.21e-05	0.00086	CcSEcCtD
Eprosartan—Headache—Irinotecan—pancreatic cancer	9.16e-05	0.000856	CcSEcCtD
Eprosartan—Insomnia—Docetaxel—pancreatic cancer	9.14e-05	0.000854	CcSEcCtD
Eprosartan—Paraesthesia—Docetaxel—pancreatic cancer	9.08e-05	0.000848	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—SSTR1—pancreatic cancer	9.08e-05	0.00381	CbGpPWpGaD
Eprosartan—Vomiting—Gemcitabine—pancreatic cancer	9.06e-05	0.000846	CcSEcCtD
Eprosartan—Bradycardia—Doxorubicin—pancreatic cancer	9.04e-05	0.000844	CcSEcCtD
Eprosartan—Dyspnoea—Docetaxel—pancreatic cancer	9.01e-05	0.000842	CcSEcCtD
Eprosartan—Somnolence—Docetaxel—pancreatic cancer	8.99e-05	0.000839	CcSEcCtD
Eprosartan—Rash—Gemcitabine—pancreatic cancer	8.98e-05	0.000839	CcSEcCtD
Eprosartan—Dermatitis—Gemcitabine—pancreatic cancer	8.97e-05	0.000838	CcSEcCtD
Eprosartan—Tinnitus—Epirubicin—pancreatic cancer	8.95e-05	0.000836	CcSEcCtD
Eprosartan—Headache—Gemcitabine—pancreatic cancer	8.92e-05	0.000833	CcSEcCtD
Eprosartan—Vomiting—Fluorouracil—pancreatic cancer	8.91e-05	0.000832	CcSEcCtD
Eprosartan—Rhinitis—Doxorubicin—pancreatic cancer	8.9e-05	0.000831	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—PPY—pancreatic cancer	8.9e-05	0.00374	CbGpPWpGaD
Eprosartan—Dyspepsia—Docetaxel—pancreatic cancer	8.9e-05	0.000831	CcSEcCtD
Eprosartan—Rash—Fluorouracil—pancreatic cancer	8.83e-05	0.000825	CcSEcCtD
Eprosartan—Dermatitis—Fluorouracil—pancreatic cancer	8.82e-05	0.000824	CcSEcCtD
Eprosartan—Pharyngitis—Doxorubicin—pancreatic cancer	8.81e-05	0.000823	CcSEcCtD
Eprosartan—AGTR1—GPCR ligand binding—SST—pancreatic cancer	8.8e-05	0.0037	CbGpPWpGaD
Eprosartan—Decreased appetite—Docetaxel—pancreatic cancer	8.79e-05	0.000821	CcSEcCtD
Eprosartan—Headache—Fluorouracil—pancreatic cancer	8.77e-05	0.000819	CcSEcCtD
Eprosartan—Oedema peripheral—Doxorubicin—pancreatic cancer	8.75e-05	0.000817	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—SSTR2—pancreatic cancer	8.74e-05	0.00367	CbGpPWpGaD
Eprosartan—Fatigue—Docetaxel—pancreatic cancer	8.72e-05	0.000814	CcSEcCtD
Eprosartan—Nausea—Irinotecan—pancreatic cancer	8.69e-05	0.000811	CcSEcCtD
Eprosartan—Pain—Docetaxel—pancreatic cancer	8.65e-05	0.000807	CcSEcCtD
Eprosartan—Constipation—Docetaxel—pancreatic cancer	8.65e-05	0.000807	CcSEcCtD
Eprosartan—Chills—Epirubicin—pancreatic cancer	8.61e-05	0.000804	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—SSTR3—pancreatic cancer	8.6e-05	0.00361	CbGpPWpGaD
Eprosartan—Visual impairment—Doxorubicin—pancreatic cancer	8.56e-05	0.000799	CcSEcCtD
Eprosartan—Nausea—Gemcitabine—pancreatic cancer	8.46e-05	0.00079	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—CCKBR—pancreatic cancer	8.44e-05	0.00355	CbGpPWpGaD
Eprosartan—Feeling abnormal—Docetaxel—pancreatic cancer	8.33e-05	0.000778	CcSEcCtD
Eprosartan—Nausea—Fluorouracil—pancreatic cancer	8.32e-05	0.000777	CcSEcCtD
Eprosartan—Tinnitus—Doxorubicin—pancreatic cancer	8.28e-05	0.000773	CcSEcCtD
Eprosartan—Gastrointestinal pain—Docetaxel—pancreatic cancer	8.27e-05	0.000772	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—SSTR1—pancreatic cancer	8.24e-05	0.00346	CbGpPWpGaD
Eprosartan—Flatulence—Epirubicin—pancreatic cancer	8.23e-05	0.000769	CcSEcCtD
Eprosartan—Tension—Epirubicin—pancreatic cancer	8.2e-05	0.000766	CcSEcCtD
Eprosartan—AGTR1—GPCR ligand binding—CNR1—pancreatic cancer	8.12e-05	0.00341	CbGpPWpGaD
Eprosartan—Nervousness—Epirubicin—pancreatic cancer	8.11e-05	0.000758	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—PPY—pancreatic cancer	8.08e-05	0.0034	CbGpPWpGaD
Eprosartan—Back pain—Epirubicin—pancreatic cancer	8.08e-05	0.000755	CcSEcCtD
Eprosartan—Muscle spasms—Epirubicin—pancreatic cancer	8.03e-05	0.00075	CcSEcCtD
Eprosartan—Body temperature increased—Docetaxel—pancreatic cancer	7.99e-05	0.000746	CcSEcCtD
Eprosartan—Abdominal pain—Docetaxel—pancreatic cancer	7.99e-05	0.000746	CcSEcCtD
Eprosartan—Chills—Doxorubicin—pancreatic cancer	7.97e-05	0.000744	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—SSTR2—pancreatic cancer	7.93e-05	0.00333	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—GCG—pancreatic cancer	7.84e-05	0.0033	CbGpPWpGaD
Eprosartan—Ill-defined disorder—Epirubicin—pancreatic cancer	7.75e-05	0.000724	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—CCKBR—pancreatic cancer	7.66e-05	0.00322	CbGpPWpGaD
Eprosartan—Flatulence—Doxorubicin—pancreatic cancer	7.62e-05	0.000711	CcSEcCtD
Eprosartan—Tension—Doxorubicin—pancreatic cancer	7.59e-05	0.000708	CcSEcCtD
Eprosartan—Malaise—Epirubicin—pancreatic cancer	7.53e-05	0.000704	CcSEcCtD
Eprosartan—Nervousness—Doxorubicin—pancreatic cancer	7.51e-05	0.000701	CcSEcCtD
Eprosartan—Vertigo—Epirubicin—pancreatic cancer	7.51e-05	0.000701	CcSEcCtD
Eprosartan—Syncope—Epirubicin—pancreatic cancer	7.49e-05	0.0007	CcSEcCtD
Eprosartan—Back pain—Doxorubicin—pancreatic cancer	7.48e-05	0.000698	CcSEcCtD
Eprosartan—Hypersensitivity—Docetaxel—pancreatic cancer	7.45e-05	0.000696	CcSEcCtD
Eprosartan—Muscle spasms—Doxorubicin—pancreatic cancer	7.43e-05	0.000694	CcSEcCtD
Eprosartan—Palpitations—Epirubicin—pancreatic cancer	7.38e-05	0.000689	CcSEcCtD
Eprosartan—Loss of consciousness—Epirubicin—pancreatic cancer	7.34e-05	0.000686	CcSEcCtD
Eprosartan—Cough—Epirubicin—pancreatic cancer	7.29e-05	0.000681	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—GAST—pancreatic cancer	7.26e-05	0.00305	CbGpPWpGaD
Eprosartan—Asthenia—Docetaxel—pancreatic cancer	7.25e-05	0.000677	CcSEcCtD
Eprosartan—Ill-defined disorder—Doxorubicin—pancreatic cancer	7.17e-05	0.00067	CcSEcCtD
Eprosartan—Pruritus—Docetaxel—pancreatic cancer	7.15e-05	0.000668	CcSEcCtD
Eprosartan—Myalgia—Epirubicin—pancreatic cancer	7.11e-05	0.000664	CcSEcCtD
Eprosartan—Arthralgia—Epirubicin—pancreatic cancer	7.11e-05	0.000664	CcSEcCtD
Eprosartan—Chest pain—Epirubicin—pancreatic cancer	7.11e-05	0.000664	CcSEcCtD
Eprosartan—Anxiety—Epirubicin—pancreatic cancer	7.09e-05	0.000662	CcSEcCtD
Eprosartan—Discomfort—Epirubicin—pancreatic cancer	7.03e-05	0.000656	CcSEcCtD
Eprosartan—Malaise—Doxorubicin—pancreatic cancer	6.97e-05	0.000651	CcSEcCtD
Eprosartan—Dry mouth—Epirubicin—pancreatic cancer	6.96e-05	0.00065	CcSEcCtD
Eprosartan—Vertigo—Doxorubicin—pancreatic cancer	6.95e-05	0.000649	CcSEcCtD
Eprosartan—Syncope—Doxorubicin—pancreatic cancer	6.93e-05	0.000647	CcSEcCtD
Eprosartan—Diarrhoea—Docetaxel—pancreatic cancer	6.92e-05	0.000646	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—SCT—pancreatic cancer	6.88e-05	0.00289	CbGpPWpGaD
Eprosartan—Palpitations—Doxorubicin—pancreatic cancer	6.83e-05	0.000638	CcSEcCtD
Eprosartan—Loss of consciousness—Doxorubicin—pancreatic cancer	6.79e-05	0.000635	CcSEcCtD
Eprosartan—Cough—Doxorubicin—pancreatic cancer	6.75e-05	0.00063	CcSEcCtD
Eprosartan—AGTR1—Peptide ligand-binding receptors—CXCL8—pancreatic cancer	6.71e-05	0.00282	CbGpPWpGaD
Eprosartan—Shock—Epirubicin—pancreatic cancer	6.71e-05	0.000626	CcSEcCtD
Eprosartan—Dizziness—Docetaxel—pancreatic cancer	6.69e-05	0.000624	CcSEcCtD
Eprosartan—Thrombocytopenia—Epirubicin—pancreatic cancer	6.68e-05	0.000623	CcSEcCtD
Eprosartan—Tachycardia—Epirubicin—pancreatic cancer	6.66e-05	0.000621	CcSEcCtD
Eprosartan—Hyperhidrosis—Epirubicin—pancreatic cancer	6.59e-05	0.000616	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—GAST—pancreatic cancer	6.59e-05	0.00277	CbGpPWpGaD
Eprosartan—Arthralgia—Doxorubicin—pancreatic cancer	6.58e-05	0.000615	CcSEcCtD
Eprosartan—Myalgia—Doxorubicin—pancreatic cancer	6.58e-05	0.000615	CcSEcCtD
Eprosartan—Chest pain—Doxorubicin—pancreatic cancer	6.58e-05	0.000615	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—CCK—pancreatic cancer	6.56e-05	0.00276	CbGpPWpGaD
Eprosartan—Anxiety—Doxorubicin—pancreatic cancer	6.56e-05	0.000612	CcSEcCtD
Eprosartan—Discomfort—Doxorubicin—pancreatic cancer	6.5e-05	0.000607	CcSEcCtD
Eprosartan—Anorexia—Epirubicin—pancreatic cancer	6.5e-05	0.000607	CcSEcCtD
Eprosartan—Dry mouth—Doxorubicin—pancreatic cancer	6.44e-05	0.000601	CcSEcCtD
Eprosartan—Vomiting—Docetaxel—pancreatic cancer	6.43e-05	0.0006	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—GLP1R—pancreatic cancer	6.4e-05	0.00269	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—CNR2—pancreatic cancer	6.4e-05	0.00269	CbGpPWpGaD
Eprosartan—Rash—Docetaxel—pancreatic cancer	6.37e-05	0.000595	CcSEcCtD
Eprosartan—Hypotension—Epirubicin—pancreatic cancer	6.37e-05	0.000595	CcSEcCtD
Eprosartan—Dermatitis—Docetaxel—pancreatic cancer	6.37e-05	0.000595	CcSEcCtD
Eprosartan—Headache—Docetaxel—pancreatic cancer	6.33e-05	0.000591	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—CCKAR—pancreatic cancer	6.29e-05	0.00264	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—SCT—pancreatic cancer	6.25e-05	0.00262	CbGpPWpGaD
Eprosartan—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	6.21e-05	0.00058	CcSEcCtD
Eprosartan—Shock—Doxorubicin—pancreatic cancer	6.21e-05	0.00058	CcSEcCtD
Eprosartan—Thrombocytopenia—Doxorubicin—pancreatic cancer	6.18e-05	0.000577	CcSEcCtD
Eprosartan—Insomnia—Epirubicin—pancreatic cancer	6.17e-05	0.000576	CcSEcCtD
Eprosartan—Tachycardia—Doxorubicin—pancreatic cancer	6.16e-05	0.000575	CcSEcCtD
Eprosartan—Paraesthesia—Epirubicin—pancreatic cancer	6.12e-05	0.000572	CcSEcCtD
Eprosartan—Hyperhidrosis—Doxorubicin—pancreatic cancer	6.1e-05	0.00057	CcSEcCtD
Eprosartan—Dyspnoea—Epirubicin—pancreatic cancer	6.08e-05	0.000568	CcSEcCtD
Eprosartan—Somnolence—Epirubicin—pancreatic cancer	6.06e-05	0.000566	CcSEcCtD
Eprosartan—Anorexia—Doxorubicin—pancreatic cancer	6.01e-05	0.000562	CcSEcCtD
Eprosartan—Nausea—Docetaxel—pancreatic cancer	6.01e-05	0.000561	CcSEcCtD
Eprosartan—Dyspepsia—Epirubicin—pancreatic cancer	6e-05	0.000561	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—PRLHR—pancreatic cancer	5.97e-05	0.00251	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CCK—pancreatic cancer	5.96e-05	0.0025	CbGpPWpGaD
Eprosartan—Decreased appetite—Epirubicin—pancreatic cancer	5.93e-05	0.000554	CcSEcCtD
Eprosartan—Hypotension—Doxorubicin—pancreatic cancer	5.9e-05	0.000551	CcSEcCtD
Eprosartan—Fatigue—Epirubicin—pancreatic cancer	5.88e-05	0.000549	CcSEcCtD
Eprosartan—Pain—Epirubicin—pancreatic cancer	5.83e-05	0.000545	CcSEcCtD
Eprosartan—Constipation—Epirubicin—pancreatic cancer	5.83e-05	0.000545	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—CNR2—pancreatic cancer	5.81e-05	0.00244	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—GLP1R—pancreatic cancer	5.81e-05	0.00244	CbGpPWpGaD
Eprosartan—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	5.75e-05	0.000537	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—CCKAR—pancreatic cancer	5.71e-05	0.0024	CbGpPWpGaD
Eprosartan—Insomnia—Doxorubicin—pancreatic cancer	5.71e-05	0.000533	CcSEcCtD
Eprosartan—Paraesthesia—Doxorubicin—pancreatic cancer	5.67e-05	0.000529	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—IAPP—pancreatic cancer	5.66e-05	0.00238	CbGpPWpGaD
Eprosartan—Dyspnoea—Doxorubicin—pancreatic cancer	5.63e-05	0.000525	CcSEcCtD
Eprosartan—Feeling abnormal—Epirubicin—pancreatic cancer	5.62e-05	0.000525	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—ACVR1B—pancreatic cancer	5.62e-05	0.00236	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ZNRF3—pancreatic cancer	5.62e-05	0.00236	CbGpPWpGaD
Eprosartan—Somnolence—Doxorubicin—pancreatic cancer	5.61e-05	0.000524	CcSEcCtD
Eprosartan—Gastrointestinal pain—Epirubicin—pancreatic cancer	5.58e-05	0.000521	CcSEcCtD
Eprosartan—Dyspepsia—Doxorubicin—pancreatic cancer	5.55e-05	0.000519	CcSEcCtD
Eprosartan—CYP2C9—Arachidonic acid metabolism—PTGS2—pancreatic cancer	5.52e-05	0.00232	CbGpPWpGaD
Eprosartan—Decreased appetite—Doxorubicin—pancreatic cancer	5.48e-05	0.000512	CcSEcCtD
Eprosartan—Fatigue—Doxorubicin—pancreatic cancer	5.44e-05	0.000508	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—PTHLH—pancreatic cancer	5.44e-05	0.00228	CbGpPWpGaD
Eprosartan—Urticaria—Epirubicin—pancreatic cancer	5.42e-05	0.000506	CcSEcCtD
Eprosartan—Pain—Doxorubicin—pancreatic cancer	5.4e-05	0.000504	CcSEcCtD
Eprosartan—Constipation—Doxorubicin—pancreatic cancer	5.4e-05	0.000504	CcSEcCtD
Eprosartan—Body temperature increased—Epirubicin—pancreatic cancer	5.39e-05	0.000503	CcSEcCtD
Eprosartan—Abdominal pain—Epirubicin—pancreatic cancer	5.39e-05	0.000503	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—SHH—pancreatic cancer	5.21e-05	0.00219	CbGpPWpGaD
Eprosartan—Feeling abnormal—Doxorubicin—pancreatic cancer	5.2e-05	0.000486	CcSEcCtD
Eprosartan—Gastrointestinal pain—Doxorubicin—pancreatic cancer	5.16e-05	0.000482	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—IAPP—pancreatic cancer	5.14e-05	0.00216	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	5.1e-05	0.00214	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—DTX1—pancreatic cancer	5.08e-05	0.00213	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SSTR3—pancreatic cancer	5.08e-05	0.00213	CbGpPWpGaD
Eprosartan—Hypersensitivity—Epirubicin—pancreatic cancer	5.02e-05	0.000469	CcSEcCtD
Eprosartan—Urticaria—Doxorubicin—pancreatic cancer	5.01e-05	0.000468	CcSEcCtD
Eprosartan—Body temperature increased—Doxorubicin—pancreatic cancer	4.99e-05	0.000466	CcSEcCtD
Eprosartan—Abdominal pain—Doxorubicin—pancreatic cancer	4.99e-05	0.000466	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—SST—pancreatic cancer	4.97e-05	0.00209	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PTHLH—pancreatic cancer	4.94e-05	0.00207	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PTCH1—pancreatic cancer	4.94e-05	0.00207	CbGpPWpGaD
Eprosartan—Asthenia—Epirubicin—pancreatic cancer	4.89e-05	0.000457	CcSEcCtD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—pancreatic cancer	4.88e-05	0.00205	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SSTR1—pancreatic cancer	4.87e-05	0.00205	CbGpPWpGaD
Eprosartan—Pruritus—Epirubicin—pancreatic cancer	4.82e-05	0.000451	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—PPY—pancreatic cancer	4.78e-05	0.00201	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SSTR2—pancreatic cancer	4.69e-05	0.00197	CbGpPWpGaD
Eprosartan—Diarrhoea—Epirubicin—pancreatic cancer	4.67e-05	0.000436	CcSEcCtD
Eprosartan—Hypersensitivity—Doxorubicin—pancreatic cancer	4.65e-05	0.000434	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—CNR1—pancreatic cancer	4.59e-05	0.00193	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CCKBR—pancreatic cancer	4.53e-05	0.0019	CbGpPWpGaD
Eprosartan—Asthenia—Doxorubicin—pancreatic cancer	4.53e-05	0.000423	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—SST—pancreatic cancer	4.52e-05	0.0019	CbGpPWpGaD
Eprosartan—Dizziness—Epirubicin—pancreatic cancer	4.51e-05	0.000421	CcSEcCtD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	4.5e-05	0.00189	CbGpPWpGaD
Eprosartan—Pruritus—Doxorubicin—pancreatic cancer	4.46e-05	0.000417	CcSEcCtD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—pancreatic cancer	4.44e-05	0.00187	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—GCG—pancreatic cancer	4.43e-05	0.00186	CbGpPWpGaD
Eprosartan—Vomiting—Epirubicin—pancreatic cancer	4.34e-05	0.000405	CcSEcCtD
Eprosartan—Diarrhoea—Doxorubicin—pancreatic cancer	4.32e-05	0.000403	CcSEcCtD
Eprosartan—AGTR1—G alpha (q) signalling events—PIK3CA—pancreatic cancer	4.31e-05	0.00181	CbGpPWpGaD
Eprosartan—Rash—Epirubicin—pancreatic cancer	4.3e-05	0.000401	CcSEcCtD
Eprosartan—Dermatitis—Epirubicin—pancreatic cancer	4.3e-05	0.000401	CcSEcCtD
Eprosartan—Headache—Epirubicin—pancreatic cancer	4.27e-05	0.000399	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—DTX4—pancreatic cancer	4.26e-05	0.00179	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—GLI1—pancreatic cancer	4.26e-05	0.00179	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—pancreatic cancer	4.2e-05	0.00176	CbGpPWpGaD
Eprosartan—Dizziness—Doxorubicin—pancreatic cancer	4.17e-05	0.00039	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—CNR1—pancreatic cancer	4.17e-05	0.00175	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NRP1—pancreatic cancer	4.14e-05	0.00174	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PPP2R5B—pancreatic cancer	4.14e-05	0.00174	CbGpPWpGaD
Eprosartan—Nausea—Epirubicin—pancreatic cancer	4.05e-05	0.000378	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—GCG—pancreatic cancer	4.03e-05	0.00169	CbGpPWpGaD
Eprosartan—Vomiting—Doxorubicin—pancreatic cancer	4.01e-05	0.000375	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—HEY2—pancreatic cancer	3.99e-05	0.00167	CbGpPWpGaD
Eprosartan—Rash—Doxorubicin—pancreatic cancer	3.98e-05	0.000371	CcSEcCtD
Eprosartan—Dermatitis—Doxorubicin—pancreatic cancer	3.97e-05	0.000371	CcSEcCtD
Eprosartan—Headache—Doxorubicin—pancreatic cancer	3.95e-05	0.000369	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—GAST—pancreatic cancer	3.89e-05	0.00164	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—pancreatic cancer	3.86e-05	0.00162	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—TGFB1—pancreatic cancer	3.86e-05	0.00162	CbGpPWpGaD
Eprosartan—Nausea—Doxorubicin—pancreatic cancer	3.75e-05	0.00035	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—SCT—pancreatic cancer	3.69e-05	0.00155	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HEY1—pancreatic cancer	3.69e-05	0.00155	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—pancreatic cancer	3.57e-05	0.0015	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CCK—pancreatic cancer	3.52e-05	0.00148	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CNR2—pancreatic cancer	3.43e-05	0.00144	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—GLP1R—pancreatic cancer	3.43e-05	0.00144	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—CXCL8—pancreatic cancer	3.43e-05	0.00144	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CCKAR—pancreatic cancer	3.38e-05	0.00142	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—JAG2—pancreatic cancer	3.27e-05	0.00138	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MEN1—pancreatic cancer	3.23e-05	0.00136	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SHH—pancreatic cancer	3.08e-05	0.00129	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NOTCH4—pancreatic cancer	3.06e-05	0.00128	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IAPP—pancreatic cancer	3.04e-05	0.00128	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PTHLH—pancreatic cancer	2.92e-05	0.00123	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PTCH1—pancreatic cancer	2.92e-05	0.00123	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SST—pancreatic cancer	2.67e-05	0.00112	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PIK3CG—pancreatic cancer	2.63e-05	0.00111	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—JAG1—pancreatic cancer	2.61e-05	0.0011	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NOTCH3—pancreatic cancer	2.6e-05	0.00109	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CNR1—pancreatic cancer	2.46e-05	0.00103	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PIK3CG—pancreatic cancer	2.39e-05	0.001	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—GCG—pancreatic cancer	2.38e-05	0.000999	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PIK3CD—pancreatic cancer	2.31e-05	0.000972	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—STK11—pancreatic cancer	2.24e-05	0.000939	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PIK3CD—pancreatic cancer	2.1e-05	0.000883	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PIK3CB—pancreatic cancer	2.02e-05	0.000847	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SMAD4—pancreatic cancer	1.96e-05	0.000823	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—CXCL8—pancreatic cancer	1.94e-05	0.000814	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HES1—pancreatic cancer	1.91e-05	0.000803	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PRSS1—pancreatic cancer	1.84e-05	0.000774	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PIK3CB—pancreatic cancer	1.83e-05	0.000769	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CXCL8—pancreatic cancer	1.76e-05	0.000739	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TERT—pancreatic cancer	1.68e-05	0.000704	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HIF1A—pancreatic cancer	1.6e-05	0.000673	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TSC2—pancreatic cancer	1.6e-05	0.000672	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ARG2—pancreatic cancer	1.6e-05	0.000671	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—APOE—pancreatic cancer	1.56e-05	0.000657	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—KDR—pancreatic cancer	1.53e-05	0.000644	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NFKBIA—pancreatic cancer	1.46e-05	0.000612	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NOTCH1—pancreatic cancer	1.44e-05	0.000607	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PIK3CG—pancreatic cancer	1.41e-05	0.000593	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—NRAS—pancreatic cancer	1.41e-05	0.000593	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—TYMP—pancreatic cancer	1.4e-05	0.000586	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—EGF—pancreatic cancer	1.4e-05	0.000586	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—EGFR—pancreatic cancer	1.29e-05	0.00054	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PIK3CD—pancreatic cancer	1.24e-05	0.000521	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.23e-05	0.000516	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—KRAS—pancreatic cancer	1.21e-05	0.000511	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	1.15e-05	0.000484	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GLP1R—pancreatic cancer	1.12e-05	0.000473	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PIK3CA—pancreatic cancer	1.12e-05	0.000469	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—DPYD—pancreatic cancer	1.11e-05	0.000465	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PIK3CB—pancreatic cancer	1.08e-05	0.000454	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SLC2A2—pancreatic cancer	1.05e-05	0.000441	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CXCL8—pancreatic cancer	1.04e-05	0.000437	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	1.04e-05	0.000437	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—HRAS—pancreatic cancer	1.03e-05	0.000434	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—AKT1—pancreatic cancer	1e-05	0.000422	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	1e-05	0.000421	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CASP3—pancreatic cancer	9.95e-06	0.000418	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CCND1—pancreatic cancer	9.68e-06	0.000407	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CTNNB1—pancreatic cancer	9.59e-06	0.000403	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MMP9—pancreatic cancer	9.4e-06	0.000395	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PTEN—pancreatic cancer	9.35e-06	0.000393	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	9.14e-06	0.000384	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—AKT1—pancreatic cancer	9.12e-06	0.000383	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SRC—pancreatic cancer	8.67e-06	0.000364	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—VEGFA—pancreatic cancer	8.44e-06	0.000355	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—STAT3—pancreatic cancer	8.36e-06	0.000351	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NRAS—pancreatic cancer	8.34e-06	0.00035	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CD44—pancreatic cancer	8.13e-06	0.000342	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	7.96e-06	0.000335	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	7.89e-06	0.000332	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GCG—pancreatic cancer	7.8e-06	0.000328	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MYC—pancreatic cancer	7.77e-06	0.000326	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TGFB1—pancreatic cancer	7.75e-06	0.000326	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—EGFR—pancreatic cancer	7.6e-06	0.000319	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—STK11—pancreatic cancer	7.33e-06	0.000308	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—KRAS—pancreatic cancer	7.18e-06	0.000302	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	6.88e-06	0.000289	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PIK3CA—pancreatic cancer	6.59e-06	0.000277	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TP53—pancreatic cancer	6.38e-06	0.000268	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—TYMS—pancreatic cancer	6.31e-06	0.000265	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HRAS—pancreatic cancer	6.1e-06	0.000256	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—AKT1—pancreatic cancer	5.39e-06	0.000226	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—APOE—pancreatic cancer	5.13e-06	0.000216	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	4.85e-06	0.000204	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PIK3CG—pancreatic cancer	4.63e-06	0.000194	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PPARG—pancreatic cancer	4.47e-06	0.000188	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PIK3CD—pancreatic cancer	4.07e-06	0.000171	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PIK3CB—pancreatic cancer	3.55e-06	0.000149	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PTGS2—pancreatic cancer	3.51e-06	0.000148	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PTEN—pancreatic cancer	3.06e-06	0.000129	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PIK3CA—pancreatic cancer	2.16e-06	9.08e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—AKT1—pancreatic cancer	1.77e-06	7.42e-05	CbGpPWpGaD
